196 related articles for article (PubMed ID: 21385398)
1. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo.
Han JF; Cao RY; Deng YQ; Tian X; Jiang T; Qin ED; Qin CF
Virol J; 2011 Mar; 8():106. PubMed ID: 21385398
[TBL] [Abstract][Full Text] [Related]
2. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice.
Chen IC; Wang SM; Yu CK; Liu CC
Med Microbiol Immunol; 2013 Aug; 202(4):259-65. PubMed ID: 23408291
[TBL] [Abstract][Full Text] [Related]
3.
Caine EA; Osorio JE
J Virol; 2017 Mar; 91(5):. PubMed ID: 27974562
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus 71 infection of monocytes with antibody-dependent enhancement.
Wang SM; Chen IC; Su LY; Huang KJ; Lei HY; Liu CC
Clin Vaccine Immunol; 2010 Oct; 17(10):1517-23. PubMed ID: 20685937
[TBL] [Abstract][Full Text] [Related]
5. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection.
Cao RY; Dong DY; Liu RJ; Han JF; Wang GC; Zhao H; Li XF; Deng YQ; Zhu SY; Wang XY; Lin F; Zhang FJ; Chen W; Qin ED; Qin CF
PLoS One; 2013; 8(5):e64024. PubMed ID: 23700449
[TBL] [Abstract][Full Text] [Related]
6. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection.
Khong WX; Yan B; Yeo H; Tan EL; Lee JJ; Ng JK; Chow VT; Alonso S
J Virol; 2012 Feb; 86(4):2121-31. PubMed ID: 22130542
[TBL] [Abstract][Full Text] [Related]
7. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.
Cao L; Mao F; Pang Z; Yi Y; Qiu F; Tian R; Meng Q; Jia Z; Bi S
Mol Med Rep; 2015 Aug; 12(2):2473-80. PubMed ID: 25936344
[TBL] [Abstract][Full Text] [Related]
9. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
[TBL] [Abstract][Full Text] [Related]
10. CD4 T-cell-independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads.
Wang LC; Kao CM; Ling P; Su IJ; Chang TM; Chen SH
Clin Dev Immunol; 2012; 2012():580696. PubMed ID: 23133489
[TBL] [Abstract][Full Text] [Related]
11. A Novel Murine Model Expressing a Chimeric mSCARB2/hSCARB2 Receptor Is Highly Susceptible to Oral Infection with Clinical Isolates of Enterovirus 71.
Yang CH; Liang CT; Jiang ST; Chen KH; Yang CC; Cheng ML; Ho HY
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894476
[TBL] [Abstract][Full Text] [Related]
12. VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.
Fujii K; Sudaka Y; Takashino A; Kobayashi K; Kataoka C; Suzuki T; Iwata-Yoshikawa N; Kotani O; Ami Y; Shimizu H; Nagata N; Mizuta K; Matsuzaki Y; Koike S
J Virol; 2018 Aug; 92(15):. PubMed ID: 29848582
[TBL] [Abstract][Full Text] [Related]
13. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
14. A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children.
Huang KY; Lin JJ; Chiu CH; Yang S; Tsao KC; Huang YC; Lin TY
J Infect Dis; 2015 Sep; 212(5):808-17. PubMed ID: 25712974
[TBL] [Abstract][Full Text] [Related]
15. Viral and host factors that contribute to pathogenicity of enterovirus 71.
Huang HI; Weng KF; Shih SR
Future Microbiol; 2012 Apr; 7(4):467-79. PubMed ID: 22439724
[TBL] [Abstract][Full Text] [Related]
16. Association of viral replication capacity with the pathogenicity of enterovirus 71.
Sun LL; Wang JK; Cui XQ; Hao SB; Li J; Zhao L; Yuan XJ; Wen HL; Yu XJ; Wang ZY
Virus Res; 2014 Aug; 189():1-7. PubMed ID: 24792876
[TBL] [Abstract][Full Text] [Related]
17. Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy.
Shih C; Liao CC; Chang YS; Wu SY; Chang CS; Liou AT
Viruses; 2018 Nov; 10(12):. PubMed ID: 30487421
[TBL] [Abstract][Full Text] [Related]
18. Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy.
Liu P; Yuan Y; Cui B; Huo Y; Bian L; Chen L; Liu S; Wang C; Xu Y; Tedcastle A; Gao F; Mao Q; Martin J; Liang Z
Viruses; 2021 Apr; 13(5):. PubMed ID: 33919184
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody against EV71 3D
Li Y; Yu J; Qi X; Yan H
BMC Immunol; 2019 Jan; 20(1):6. PubMed ID: 30669993
[TBL] [Abstract][Full Text] [Related]
20. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model.
Khong WX; Foo DG; Trasti SL; Tan EL; Alonso S
J Virol; 2011 Apr; 85(7):3067-76. PubMed ID: 21228224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
